Yükleniyor... / Loading...
This study examined the effect of immunoadsorption, a method that removes certain antibodies from the blood, in patients with chronic fatigue syndrome (ME/CFS), including those with post-COVID-19 CFS. It enrolled patients aged 18-65 who met the diagnostic criteria and had certain autoantibodies detected in their blood. It was a trial without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Subjects of all genders ≥18 \<65 years at time of informed consent * Diagnosed ME/CFS according to Canadian consensus criteria (CCC) 2003 including patients with PACS-CFS at screening with Bell Score ≥20 and ≤50 * Detection of at least one kind of autoantibodies measured during screening (among others antineuronal-, ß2-adrenergic-receptor-, muscarine-receptorantibodies) in serum or CSF Exclusion Criteria: * Comorbidity bearing risk that patient might not tolerate treatment as judged by investigator including among others: * malignant disease within the last 5 years * clinically meaningful laboratory abnormalities * moderate to severe renal insufficiency * cardiac insufficiency with an LVEF lower than 40%, uncontrolled cardiac arrhythmia, severe coronary heart disease * severe Hypercoagulability * Acute or severe psychiatric disease * Current indispensable medication with ACE inhibitors * Fatigue duration for ≥5 years * Presence of other conditions or differential diagnosis better explaining the symptoms of the patient than the suspected ME/CFS * Ongoing immunosuppressive therapy * Active/acute infectious diseases like TBC, HIV, CMV, EBV, HBV, HBC